Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant 2019 03;25(3):e89-e97

Date

11/09/2018

Pubmed ID

30408566

Pubmed Central ID

PMC6445685

DOI

10.1016/j.bbmt.2018.11.001

Scopus ID

2-s2.0-85057956613   5 Citations

Abstract

The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.

Author List

Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PL

Author

Marcelo C. Pasquini MD, MS Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Bone Marrow Transplantation
Clinical Trials as Topic
Congresses as Topic
Education
Humans
Immunologic Factors
Multiple Myeloma
Neoplasm, Residual
Societies, Scientific
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a